Does the media prefer CAPR or NTLA?

In the previous week, Intellia Therapeutics had 1 more articles in the media than Capricor Therapeutics. MarketBeat recorded 12 mentions for Intellia Therapeutics and 11 mentions for Capricor Therapeutics. Intellia Therapeutics' average media sentiment score of 0.67 beat Capricor Therapeutics' score of 0.26 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GENB or CAPR more profitable?

Generate Biomedicines' return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Generate Biomedicines N/A N/A N/A Capricor Therapeutics N/A -56.60% -43.97%

Does the media refer more to GENB or CAPR?

In the previous week, Capricor Therapeutics had 3 more articles in the media than Generate Biomedicines. MarketBeat recorded 11 mentions for Capricor Therapeutics and 8 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.43 beat Capricor Therapeutics' score of 0.26 indicating that Generate Biomedicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Generate Biomedicines 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CAPR or NUVB?

In the previous week, Capricor Therapeutics had 9 more articles in the media than Nuvation Bio. MarketBeat recorded 11 mentions for Capricor Therapeutics and 2 mentions for Nuvation Bio. Capricor Therapeutics' average media sentiment score of 0.26 beat Nuvation Bio's score of -0.14 indicating that Capricor Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CAPR or STOK?

In the previous week, Capricor Therapeutics had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 11 mentions for Capricor Therapeutics and 9 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.65 beat Capricor Therapeutics' score of 0.26 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Capricor Therapeutics (CAPR) Competitors

$7.83 -0.18 (-2.25%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.79 -0.04 (-0.46%)

As of 10/9/2026 07:51 PM Eastern

Compare

CAPR vs. NTLA, GENB, SEPN, NUVB, and STOK

Should you buy Capricor Therapeutics stock or one of its competitors? Capricor Therapeutics's main competitors and comparable companies include Intellia Therapeutics (NTLA), Generate Biomedicines (GENB), Septerna (SEPN), Nuvation Bio (NUVB), and Stoke Therapeutics (STOK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Capricor Therapeutics compare to Intellia Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Capricor Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Capricor Therapeutics' return on equity of -56.60% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Capricor Therapeutics presently has a consensus price target of $30.25, indicating a potential upside of 286.33%. Intellia Therapeutics has a consensus price target of $20.72, indicating a potential upside of 58.51%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Intellia Therapeutics	5 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.26

In the previous week, Intellia Therapeutics had 1 more articles in the media than Capricor Therapeutics. MarketBeat recorded 12 mentions for Intellia Therapeutics and 11 mentions for Capricor Therapeutics. Intellia Therapeutics' average media sentiment score of 0.67 beat Capricor Therapeutics' score of 0.26 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	20.44	-$105.04M	-$2.45	N/A
Intellia Therapeutics	$67.67M	27.07	-$412.69M	-$3.36	N/A

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Capricor Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Summary

Capricor Therapeutics beats Intellia Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Capricor Therapeutics compare to Generate Biomedicines?

Generate Biomedicines (NASDAQ:GENB) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Generate Biomedicines presently has a consensus price target of $26.40, indicating a potential upside of 84.10%. Capricor Therapeutics has a consensus price target of $30.25, indicating a potential upside of 286.33%. Given Capricor Therapeutics' higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Generate Biomedicines	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Capricor Therapeutics has lower revenue, but higher earnings than Generate Biomedicines. Generate Biomedicines is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Generate Biomedicines	$31.89M	57.72	-$203.15M	-$1.59	N/A
Capricor Therapeutics	$22.27M	20.44	-$105.04M	-$2.45	N/A

Generate Biomedicines' return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Generate Biomedicines	N/A	N/A	N/A
Capricor Therapeutics	N/A	-56.60%	-43.97%

21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Capricor Therapeutics had 3 more articles in the media than Generate Biomedicines. MarketBeat recorded 11 mentions for Capricor Therapeutics and 8 mentions for Generate Biomedicines. Generate Biomedicines' average media sentiment score of 0.43 beat Capricor Therapeutics' score of 0.26 indicating that Generate Biomedicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Generate Biomedicines	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Generate Biomedicines beats Capricor Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Capricor Therapeutics compare to Septerna?

Capricor Therapeutics (NASDAQ:CAPR) and Septerna (NASDAQ:SEPN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Septerna has higher revenue and earnings than Capricor Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	20.44	-$105.04M	-$2.45	N/A
Septerna	$45.95M	38.98	-$48.88M	-$0.54	N/A

In the previous week, Capricor Therapeutics had 10 more articles in the media than Septerna. MarketBeat recorded 11 mentions for Capricor Therapeutics and 1 mentions for Septerna. Septerna's average media sentiment score of 1.49 beat Capricor Therapeutics' score of 0.26 indicating that Septerna is being referred to more favorably in the news media.

Company	Overall Sentiment
Capricor Therapeutics	Neutral
Septerna	Positive

Capricor Therapeutics presently has a consensus price target of $30.25, suggesting a potential upside of 286.33%. Septerna has a consensus price target of $52.44, suggesting a potential upside of 36.68%. Given Capricor Therapeutics' higher possible upside, analysts plainly believe Capricor Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Capricor Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, indicating that its share price is 129% more volatile than the broader market.

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Capricor Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Septerna	-24.51%	-9.57%	-6.28%

Summary

Septerna beats Capricor Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Capricor Therapeutics compare to Nuvation Bio?

Capricor Therapeutics (NASDAQ:CAPR) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Capricor Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Nuvation Bio's return on equity of -46.59% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Nuvation Bio	-88.18%	-46.59%	-22.01%

Capricor Therapeutics currently has a consensus target price of $30.25, suggesting a potential upside of 286.33%. Nuvation Bio has a consensus target price of $13.22, suggesting a potential upside of 164.18%. Given Capricor Therapeutics' higher probable upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Capricor Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

Capricor Therapeutics has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	20.44	-$105.04M	-$2.45	N/A
Nuvation Bio	$62.90M	27.94	-$204.63M	-$0.44	N/A

In the previous week, Capricor Therapeutics had 9 more articles in the media than Nuvation Bio. MarketBeat recorded 11 mentions for Capricor Therapeutics and 2 mentions for Nuvation Bio. Capricor Therapeutics' average media sentiment score of 0.26 beat Nuvation Bio's score of -0.14 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvation Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Nuvation Bio beats Capricor Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Capricor Therapeutics compare to Stoke Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

Stoke Therapeutics has higher revenue and earnings than Capricor Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	20.44	-$105.04M	-$2.45	N/A
Stoke Therapeutics	$184.42M	8.66	-$6.89M	-$3.34	N/A

In the previous week, Capricor Therapeutics had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 11 mentions for Capricor Therapeutics and 9 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.65 beat Capricor Therapeutics' score of 0.26 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Capricor Therapeutics presently has a consensus price target of $30.25, suggesting a potential upside of 286.33%. Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 78.86%. Given Capricor Therapeutics' higher possible upside, equities analysts plainly believe Capricor Therapeutics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Capricor Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Capricor Therapeutics' return on equity of -56.60% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Summary

Capricor Therapeutics beats Stoke Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPR vs. The Competition

Export

Metric	Capricor Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$455.23M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-3.20	13.55	274.99	26.14
Price / Sales	20.44	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	1.42	17.17	11.22	6.33
Net Income	-$105.04M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-12.51%	-1.34%	-0.89%	-1.40%
1 Month Performance	-5.66%	-8.45%	-4.42%	-3.47%
1 Year Performance	10.44%	14.02%	7.03%	1.18%

Capricor Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPR Capricor Therapeutics	2.9426 of 5 stars	$7.83 -2.2%	$30.25 +286.3%	+2.8%	$455.23M	$22.27M	N/A	231	Analyst Forecast
NTLA Intellia Therapeutics	3.2968 of 5 stars	$12.37 -3.0%	$20.72 +67.5%	-48.7%	$1.79B	$67.67M	N/A	377	News Coverage Positive News Analyst Forecast
GENB Generate Biomedicines	2.4455 of 5 stars	$13.80 -0.8%	$26.40 +91.3%	N/A	$1.79B	$31.89M	N/A	312
SEPN Septerna	2.6337 of 5 stars	$35.67 -5.8%	$52.44 +47.0%	+65.8%	$1.77B	$45.95M	N/A	130	Positive News
NUVB Nuvation Bio	2.5076 of 5 stars	$4.86 -1.7%	$13.22 +171.8%	+33.5%	$1.74B	$62.90M	N/A	305	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Competitors

CAPR vs. NTLA, GENB, SEPN, NUVB, and STOK

How does Capricor Therapeutics compare to Intellia Therapeutics?

Summary

How does Capricor Therapeutics compare to Generate Biomedicines?

Summary

How does Capricor Therapeutics compare to Septerna?

Summary

How does Capricor Therapeutics compare to Nuvation Bio?

Summary

How does Capricor Therapeutics compare to Stoke Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Competitors

CAPR vs. NTLA, GENB, SEPN, NUVB, and STOK

How does Capricor Therapeutics compare to Intellia Therapeutics?

Is CAPR or NTLA more profitable?

Do analysts prefer CAPR or NTLA?

Does the media prefer CAPR or NTLA?

Which has preferable valuation & earnings, CAPR or NTLA?

Do institutionals and insiders believe in CAPR or NTLA?

Which has more risk & volatility, CAPR or NTLA?

Summary

How does Capricor Therapeutics compare to Generate Biomedicines?

Do analysts rate GENB or CAPR?

Which has higher valuation and earnings, GENB or CAPR?

Is GENB or CAPR more profitable?

Do insiders and institutionals have more ownership in GENB or CAPR?

Does the media refer more to GENB or CAPR?

Summary

How does Capricor Therapeutics compare to Septerna?

Which has better valuation & earnings, CAPR or SEPN?

Does the media refer more to CAPR or SEPN?

Do analysts prefer CAPR or SEPN?

Which has more risk & volatility, CAPR or SEPN?

Do insiders & institutionals hold more shares of CAPR or SEPN?

Is CAPR or SEPN more profitable?

Summary

How does Capricor Therapeutics compare to Nuvation Bio?

Do insiders and institutionals hold more shares of CAPR or NUVB?

Is CAPR or NUVB more profitable?

Do analysts prefer CAPR or NUVB?

Which has more risk and volatility, CAPR or NUVB?

Which has higher valuation and earnings, CAPR or NUVB?

Does the media refer more to CAPR or NUVB?

Summary

How does Capricor Therapeutics compare to Stoke Therapeutics?

Which has preferable earnings & valuation, CAPR or STOK?

Does the media prefer CAPR or STOK?

Which has more volatility and risk, CAPR or STOK?

Do analysts prefer CAPR or STOK?

Do insiders & institutionals believe in CAPR or STOK?

Is CAPR or STOK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools